Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non–small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status. METHODS: Adults with stage IV/recurrent non...

Descripción completa

Detalles Bibliográficos
Autores principales: Brahmer, Julie R., Lee, Jong-Seok, Ciuleanu, Tudor-Eliade, Bernabe Caro, Reyes, Nishio, Makoto, Urban, Laszlo, Audigier-Valette, Clarisse, Lupinacci, Lorena, Sangha, Randeep, Pluzanski, Adam, Burgers, Jacobus, Mahave, Mauricio, Ahmed, Samreen, Schoenfeld, Adam J., Paz-Ares, Luis G., Reck, Martin, Borghaei, Hossein, O'Byrne, Kenneth J., Gupta, Ravi G., Bushong, Judith, Li, Li, Blum, Steven I., Eccles, Laura J., Ramalingam, Suresh S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937094/
https://www.ncbi.nlm.nih.gov/pubmed/36223558
http://dx.doi.org/10.1200/JCO.22.01503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937094/
https://www.ncbi.nlm.nih.gov/pubmed/36223558
http://dx.doi.org/10.1200/JCO.22.01503

Ejemplares similares